Editorial
Empagliflozin reduces albuminuria—a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial
Abstract
Nowadays, type 2 diabetes care covers much more than lowering of blood glucose. To prevent and treat both micro- and macrovascular complications, risk factors like blood pressure and dyslipidemia are equally important treatment targets.
